Calidi Biotherapeutics, INC

Calidi Biotherapeutics announced a 1-for-16 reverse stock split, effective July 30, 2026, to increase its share price and maintain NYSE American listing.

Calidi Biotherapeutics has entered into a new lease agreement for office and laboratory space, anticipating significant annual cost reductions.

Calidi Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all presented proposals, including director election, auditor ratification, a reverse stock split, and a plan amendment, were approved.

Calidi Biotherapeutics has amended a previously issued warrant to include stockholder approval requirements and adjust vesting terms.

Calidi Biotherapeutics announced first quarter 2026 financial results, highlighting progress in its CLD-401 and RedTail platform development, alongside a significant reduction in administrative expenses.

Calidi Biotherapeutics has issued a warrant to an accredited investor for up to 17,391,304 shares, contingent on future stock purchases.

Calidi Biotherapeutics reports a net loss of $4.1 million for Q1 2026, with a focus on advancing its RedTail platform and securing future funding.

Calidi Biotherapeutics reported a net loss of $16.0 million for the first nine months of 2025, a decrease from the prior year, while significantly increasing its cash position through multiple equity financings.

Calidi Biotherapeutics reported a reduced net loss for the first half of 2025, driven by lower administrative costs, but faces ongoing liquidity challenges and a going concern warning.

Calidi Biotherapeutics announces its Q1 2025 financial results, highlighting ongoing research and development efforts amidst a leadership transition and concerns about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $5.1 million for Q3 2024, with ongoing concerns about its ability to continue as a going concern.

Calidi Biotherapeutics reports a net loss of $5.8 million for Q2 2024 and $13.0 million for the first half of 2024, while also expressing substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its RedTail platform and securing recent financings.

Calidi Biotherapeutics outlines its capital structure, clinical trial progress, and regulatory landscape in its annual 10-K filing, highlighting both opportunities and challenges for its novel immuno-oncology platforms.

Calidi Biotherapeutics details its capital structure, stock options, warrants, and strategic plans for advancing its immuno-oncology pipeline in its annual 10-K filing.

Calidi Biotherapeutics Director Allan Camaisa sold 850 shares of common stock for $1.455 per share for estate and tax planning purposes.

Calidi Biotherapeutics' CEO, Eric Poma, was granted 10,000 incentive stock options at an exercise price of $1.58, vesting over a multi-year period.

Calidi Biotherapeutics' Chief Scientific Officer, Antonio Fernandez Santidrian, was granted 35,000 incentive stock options at an exercise price of $1.58.

Calidi Biotherapeutics' Chief Financial Officer, Andrew C. Jackson, received a grant of 30,000 incentive stock options at an exercise price of $1.58.

Calidi Biotherapeutics Director James A. Schoeneck purchased 75,000 common shares and warrants in a public offering on August 21, 2025, for $2.00 per unit.

Calidi Biotherapeutics CEO Eric Poma acquired 25,000 common shares and accompanying warrants in a public offering.

CALIDI BIOTHERAPEUTICS, INC. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.

Calidi Biotherapeutics, Inc. is calling its stockholders to a virtual Annual Meeting on July 9, 2025, to vote on key proposals including a discretionary reverse stock split, an increase in its equity incentive plan shares, and the ratification of its new independent auditor.

Calidi Biotherapeutics will hold its annual stockholders meeting virtually on September 20, 2024, to vote on the election of directors and ratification of the appointment of auditors.

Calidi Biotherapeutics is holding a special meeting to seek stockholder approval for a reverse stock split, the conversion of convertible notes, and a standby equity purchase agreement to enhance financial flexibility.

Calidi Biotherapeutics, a clinical-stage biotechnology company, is offering up to 1.2 million common stock units and pre-funded warrant units to raise approximately $5.1 million in net proceeds, as it faces recurring losses and substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics, a clinical-stage biotechnology company, filed an S-1 registration statement for the resale of up to 6.35 million common shares, detailing its novel oncolytic virus platforms, recent management changes, and persistent financial challenges including substantial operating losses and a going concern warning.

Calidi Biotherapeutics has filed a registration statement for the resale of 6.9 million shares of its common stock by existing stockholders.

Calidi Biotherapeutics plans to offer common stock units and warrants to raise capital, as detailed in its S-1/A filing.

Calidi Biotherapeutics plans to offer common stock units and pre-funded warrant units, along with associated warrants, aiming to raise capital for working capital and general corporate purposes.

Calidi Biotherapeutics files an amendment to its Form S-1 registration statement to include updated exhibits and legal opinions related to its proposed offering.

Ognian Anguelov Gavrilov has reduced his beneficial ownership in Calidi Biotherapeutics, Inc. to 0.3% of outstanding common stock.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Calidi Biotherapeutics, Inc. common stock as of March 31, 2026.

Lincoln Alternative Strategies LLC reports 0% beneficial ownership in Calidi Biotherapeutics, Inc., indicating a full divestment of its previous stake.

Ognian Anguelov Gavrilov has disclosed a 7.78% beneficial ownership stake in Calidi Biotherapeutics, Inc., a filing that was submitted late due to an inadvertent oversight.

Lincoln Alternative Strategies LLC has reported a 14.46% beneficial ownership stake in Calidi Biotherapeutics, Inc., holding 730,000 shares of common stock.

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Calidi Biotherapeutics, Inc.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Calidi Biotherapeutics, Inc., holding 3,359,661 shares of common stock as of March 31, 2025.